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Abstract
Background: Only a limited number of studies have performed comprehensive investigations of
coding variation in relation to breast cancer risk. Given the established role of estrogens in breast
cancer, we hypothesized that coding variation in steroid receptor coactivator and corepressor
genes may alter inter-individual response to estrogen and serve as markers of breast cancer risk.
Methods: We sequenced the coding exons of 17 genes (EP300, CCND1, NME1, NCOA1, NCOA2,
NCOA3, SMARCA4, SMARCA2, CARM1, FOXA1, MPG, NCOR1, NCOR2, CALCOCO1, PRMT1, PPARBP
and CREBBP) suggested to influence transcriptional activation by steroid hormone receptors in a
multiethnic panel of women with advanced breast cancer (n = 95): African Americans, Latinos,
Japanese, Native Hawaiians and European Americans. Association testing of validated coding
variants was conducted in a breast cancer case-control study (1,612 invasive cases and 1,961
controls) nested in the Multiethnic Cohort. We used logistic regression to estimate odds ratios for
allelic effects in ethnic-pooled analyses as well as in subgroups defined by disease stage and steroid
hormone receptor status. We also investigated effect modification by established breast cancer risk
factors that are associated with steroid hormone exposure.
Results: We identified 45 coding variants with frequencies ≥ 1% in any one ethnic group (43 non-
synonymous variants). We observed nominally significant positive associations with two coding
variants in ethnic-pooled analyses (NCOR2: His52Arg, OR = 1.79; 95% CI, 1.05–3.05; CALCOCO1:
Arg12His, OR = 2.29; 95% CI, 1.00–5.26). A small number of variants were associated with risk in
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disease subgroup analyses and we observed no strong evidence of effect modification by breast
cancer risk factors. Based on the large number of statistical tests conducted in this study, the
nominally significant associations that we observed may be due to chance, and will need to be
confirmed in other studies.
Conclusion: Our findings suggest that common coding variation in these candidate genes do not
make a substantial contribution to breast cancer risk in the general population. Cataloging and
testing of coding variants in coactivator and corepressor genes should continue and may serve as
a valuable resource for investigations of other hormone-related phenotypes, such as inter-
individual response to hormonal therapies used for cancer treatment and prevention.
Background
Breast cancer risk is related to lifetime exposure to steroid
hormones.[1-3] Continuous exposure to endogenous and
exogenous estrogens enhances cell proliferation in breast
tissue, which is thought to increase the chance that a spon-
taneous mutation may become fixed and lead to a malig-
nant phenotype.[4,5] Inherited polymorphisms in genes
involved in steroid hormone biosynthesis may serve as
markers of lifetime exposure to elevated levels of estrogen
and breast cancer risk.[4,6,7] While studies have demon-
strated genetic control of steroid hormone production,
associations between common genetic variation and cir-
culating hormone levels have been modest, and insuffi-
cient to alter one's risk of developing breast cancer.[8,9]
Cellular response to estrogens is mediated through estro-
gen receptors (ERα and ERβ), which upon binding to lig-
and and DNA hormone response elements, recruit
coactivator and corepressor proteins that regulate the
expression of steroid hormone target genes.[10,11] More
than 200 nuclear receptor coactivators and 40 corepres-
sors have been identified http://www.nursa.org/.[11] The
relative recruitment of coactivators versus corepressors for
a given ligand (e.g. estradiol vs tamoxifen) is tissue spe-
cific and may account for agonist vs. antagonist activity of
the same ligand in different tissues.[12,13] Polymorphic
variants in these mediators of hormonal responsiveness
could affect the functional activity of estrogen receptors
following stimulation by endogenous or exogenous (i.e.
HRT or SERMs) estrogens and lead to differences in ster-
oid hormone sensitivity which could alter one's risk of
developing breast cancer.
In this study, we systematically screened the coding exons
of steroid hormone receptor coactivator and corepressor
genes in a multiethnic panel of women with breast cancer
in an attempt to identify and catalogue potentially func-
tional coding polymorphisms that may serve as genetic
markers of breast cancer risk. We targeted 17 genes sug-
gested to influence transcriptional activation by steroid
hormone receptors (PGR, ERα, ERβ) through direct bind-
ing to these receptors or through interactions with other
well characterized co-activator/co-repressor protein com-
plexes (E1A binding protein p300 [EP300], cyclin D1
[CCND1], non-metastatic cells 1 protein [NME1], nuclear
receptor coactivator 1 [NCoA1], nuclear receptor coactiva-
tor 2 [NCoA2], nuclear receptor coactivator 3 [NCoA3],
SWI/SNF related, matrix associated, actin dependent regu-
lator of chromatin, subfamily a, member 4 [SMARCA4],
and member 2 [SMARCA2], coactivator-associated
arginine methyltransferase 1 [CARM1], forkhead box A1
[FOXA1], N-methylpurine-DNA glycosylase [MPG],
nuclear receptor co-repressor 1 [NCOR1], nuclear recep-
tor co-repressor 2 [NCOR2], calcium binding and coiled
domain 1 [CalCoCo1], protein arginine methyltrans-
ferase 1 [PRMT1], peroxisome proliferator-activated
receptor binding protein [PPARBP] and CREB binding
protein [CREBBP]). To evaluate the relationship between
coding variants in these candidate genes and breast cancer
risk, we performed association testing in a large nested
case-control study within the Multiethnic Cohort
Study.[14]
Methods
Study population
The Multiethnic Cohort Study (MEC) is a population-
based prospective cohort study that was initiated between
1993 and 1996 and includes subjects from various ethnic
groups – African-Americans and Latinos primarily from
California (mainly Los Angeles) and Native Hawaiians,
Japanese-Americans, and European Americans primarily
from Hawaii.[14] State driver's license files were the pri-
mary sources used to identify study subjects in Hawaii and
California. Additionally, in Hawaii, state voter's registra-
tion files were used, and, in California, Health Care
Financing Administration (HCFA) files were used to iden-
tify additional African American men.
All participants (n = 215,251) returned a 26-page self-
administered baseline questionnaire that obtained gen-
eral demographic, medical and risk factor information
such as ethnicity, prior medical conditions, family history
of various cancers, dietary exposures, smoking, physical
activity, body mass index (BMI), and for women, repro-
ductive history and exogenous hormone use. All partici-
pants were 45 to 75 years of age at baseline. In the cohort,BMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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incident cancer cases are identified annually through
cohort linkage to population-based cancer Surveillance,
Epidemiology, and End Results (SEER) registries in
Hawaii and Los Angeles County as well as to the Califor-
nia State cancer registry. Information on stage of disease
and estrogen and progesterone receptor status is also
obtained through the SEER registries.
Nested case-control study of breast cancer
Blood sample collection in the MEC began in 1994 and
targeted incident breast cancer cases and a random sample
of study participants to serve as controls for genetic anal-
yses. In this present study, incident cases are defined as
those diagnosed with invasive breast cancer after enroll-
ment through December 31, 2002. Cases were over 45
years of age, and consisted primarily of postmenopausal
women. Women with a previous diagnosis of breast can-
cer identified by SEER or self-report at baseline were
excluded. Controls were women without a breast cancer
diagnosis through December 31, 2002. The controls were
frequency matched to cases on ethnicity and the case's age
at diagnosis in 5-year intervals. The nested breast cancer
case-control study consists of 1,612 invasive breast cancer
cases and 1,961 controls (n, cases/n, controls: African
Americans, 345/426; Native Hawaiians, 108/290; Japa-
nese Americans, 425/419; Latinas 334/386; European
Americans, 400/440), and has been utilized previously for
numerous candidate gene association studies in the MEC.
[15-17] This study was approved by the Institutional
Review Boards at the University of Southern California
and at the University of Hawaii and informed consent was
obtained from all study participants
Laboratory methods
Polymorphism discovery
Polymorphism discovery was carried out by sequencing
the coding exons and splice-site regions of the 17 candi-
date genes in a multiethnic panel of 95 women (19 sub-
jects of each ethnic group) with advanced breast cancer
(invasive/non-localized cancer with SEER stage ≥ 2) from
the MEC. These genes were selected because they are the
focus of ongoing structural and functional studies being
conducted by the investigators. Advanced cases were tar-
geted for sequencing to increase the likelihood of detect-
ing variants that would be biologically associated with
breast cancer. This panel was selected to have ≥ 85%
power to detect a potentially functional variant of ~5%
frequency (2 of 38 chromosomes) in any one population
or an overall frequency of ~1% (2 of 190 chromosomes).
DNA was extracted from buffy coat fractions using the
Qiagen QiaAMP Blood Kit (Valencia, CA). All DNA sam-
ples were previously whole-genome amplified (WGA) by
Molecular Staging Inc. following their standard protocol
(New Haven, CT).[18]
Non-synonymous variants in the coding region or vari-
ants in known splice-site regions that were observed in >
1 individual (a minimum of 2 out of the 190 chromo-
somes) were targeted for association testing. For variants
that were observed in only one individual, we sequenced
an additional 88–91 subjects of that specific ethnic popu-
lation. This extra sequencing was performed to determine
whether the variant is extremely rare or may have been
introduced during the WGA process or through PCR-
based sequencing, with each having error rates of ~10-
6.[19] Of the 68 rare ethnic-specific variants that we
observed, 18 were confirmed (i.e. observed in ≥ 1 of the
additional 190 chromosomes and ≥ 2 of 228 chromo-
somes examined in total (~1%)), and were further exam-
ined in relation to breast cancer risk.
DNA sequencing
Bi-directional sequencing was performed on the ABI 3730
× l DNA Analyzer (Applied Biosystems, Foster City, CA).
Gene and exon specific PCR primers were obtained from
NCBI Probe Database http://www.ncbi.nlm.nih.gov/
sites/entrez?cmd=search&db=probe when available, and
PCR conditions are according to the VariantSEQr Rese-
quencing System protocol (Applied Biosystems, Foster
City, CA). In the event that PCR primers were not availa-
ble (13 exons out of 353 targeted exons), primers were
designed in-house (at least 50 bases upstream and down-
stream from the targeted exon). In the instance that an
exon exceeded approximately 550 bases or sequencing
did not yield analyzable results, internal primers were
designed. Sequencing primers were typically universal
primers obtained from ABI or internal primers, as men-
tioned above. Sequencing purification was performed
using DyeDX 96 columns (Qiagen, Valencia, CA) follow-
ing their standard protocol. PCR primers, cycling condi-
tions and details of the sequencing protocol can be
provided upon request.
PolyPhred was used for analyzing sequence traces and var-
iation discovery http://droog.mbt.washington.edu/Poly
Phred.html. [20-22] For the 17 genes evaluated in this
study (Table 1), we successfully sequenced 346 of the 355
coding exons (97.5%; > 72 kilobases (kb)), 327 in both
the forward and reverse direction, and 19 in only one
direction (a total of 367 amplicons). Each amplicon was
sequenced in 94 of the 95 subjects in the multiethnic
panel, on average. The Phred quality score was used to
assess the quality of each trace from 10 bases 5' through
10 bases 3' of each exon.[23] The average Phred quality
score was 46.6 for all exons sequenced; 86% of the ampli-
cons had a quality score ≥ 40 and 97.5% had a quality
score ≥ 30.BMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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Genotyping
The genotype of coding variants (43 non-synonymous
SNPs, 1 in/del and 1 splice-site variant) in the case-control
samples was determined using the allelic discrimination
assay.[24] Each assay was validated initially by genotyp-
ing the multiethnic sequencing panel (n = 95) and com-
paring with the sequencing results; the concordance was >
99.6%, on average. Five variants could not be genotyped
in the case-control samples because a working assay could
not be designed (FOXA1, Gly227Glu; NCOR2, Tyr19Cys,
Pro975Ser and Pro2008Ser (rs2230944); SMARCA2,
Gly1416Ala (rs3793510)). We could infer genotypes at
Pro2008Ser in NCOR2 however as this variant was found
to be in near perfect linkage disequilibrium (i.e. r2 = 1)
with Ala2007Thr (determined based on sequencing of
69–84 individuals from each of the 5 populations). The
association results for the splice-site variant in CCND1
(rs603965, Pro241Pro) in the MEC is also part of another
study (Knudsen et al. in review, 2008). Primers and
probes for all assays can be provided upon request. Qual-
ity control replicates (~5%) were included to assess the
genotyping reliability and reproducibility for the 40
assays. The average concordance for the duplicates was
99.8%, ranging from 98%–100% across all assays. All var-
iants were successfully genotyped in > 94% of cases or
controls (average call rate = 98.2%)
This study has been approved by the Institutional Review
Boards at the University of Southern California and the
University of Hawaii.
Statistical analyses
Hardy-Weinberg equilibrium was evaluated using an
exact test.[25] Unconditional logistic regression was used
to assess the association of each variant with breast cancer
risk. Allele dosage effects were examined using a log-addi-
tive model in both ethnic-specific and pooled analyses,
treating the common homozygous (i.e. wild-type) geno-
type class as the "low risk" group. Logistic regression mod-
els were fitted to estimate odds ratios associated with this
score variable treated as a linear variable, adjusted for age
and race. We also examined effect heterogeneity by breast
cancer phenotypes (e.g. stage and estrogen receptor (ER)
status). These analyses were performed using the standard
case-control approach, limiting the cases to those with a
specific phenotype (i.e. ER-positive cases) and all con-
trols, and a case-only analysis to test for differences by dis-
ease subgroup. We also examined effect modification by
established breast cancer risk factors that are associated
with steroid hormone exposure: body mass index (kg/m2)
among postmenopausal women (≥ 25 vs < 25 kg/m2), use
of hormone replacement therapy (current vs past vs never
user of estrogen or estrogen + progestin) and age at
menarche (≤ 12, vs > 12 years). Tests for interactions were
performed using the Likelihood Ratio Test (LRT). All sta-
tistical analyses were done using SAS version 9.0 (Cary,
NC).
Results
Discovery of coding variation
In resequencing of the 17 candidate genes (Table 1), we
identified 43 non-synonymous SNPs with frequencies ≥
1% in any one ethnic group and 19 of these variants were
Table 1: Candidate Estrogen Receptor Coactivator and Corepressor-related Genes.
Gene Symbol Gene Name Chromosome NM Numbera Total Exons (Coding)
EP300 E1A Binding Protein p300 22q13 NM_001429 31 (31)
CCND1 cyclin D1 11q13 NM_053056 5 (5)
NME1 non-metastatic cells 1, protein (NM23A) 17q21 NM_000269 5 (4)
NCOA1 nuclear receptor coactivator 1 2p23 NM_003743 21 (19)
NCOA2 nuclear receptor coactivator 2 8q13 NM_006540 23 (21)
NCOA3 nuclear receptor coactivator 3 20q13 NM_181659 23 (21)
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4
19p13 NM_003072 35 (34)
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2
9p24 NM_003070 34 (33)
CARM1 coactivator-associated arginine methyltransferase 1 19p13 NM_199141 16 (16)
FOXA1 forkhead box A1 14q21 NM_004496 2 (2)
MPG N-methylpurine-DNA glycosylase 16p13 NM_002434 5 (4)
NCOR1 nuclear receptor co-repressor 1 17p11-p12 NM_006311 46 (45)
NCOR2 nuclear receptor co-repressor 2 12q24 NM_006312 48 (47)
CALCOCO1 calcium binding and coiled-coil domain 1 12q13 NM_020898 15 (14)
PRMT1 protein arginine methyltransferase 1 19q13 NM_001536 11 (11)
PPARBP peroxisome proliferator-activated receptor binding protein 17q12 NM_004774 17 (17)
CREBBP CREB binding protein 16p13 NM_004380 31 (31)
a RefSeq accession number of RNA transcript in NCBIBMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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novel (see Additional file 1, Supplementary table 1). We
detected all common (≥ 5%) validated non-synonymous
SNPs in these genes reported in dbSNP. We also detected
the well known and common splice-site variant in
CCND1 (rs603965, Pro241Pro).[26] as well as a novel in-
frame deletion (Val1996/1997del) in NCOR1 in African
Americans (MAF, 0.03). Six of the candidate genes tar-
geted in this study were quite large and included > 30 cod-
ing exons (Table 1), with four of these genes containing >
7.2 kb of coding sequence (EP300, NCOR1, NCOR2 and
CREBBP). NCOR2 contained both the largest number of
coding exons (n = 47, 7.6 kb) as well as non-synonymous
variants (n = 15). In contrast, NCOR1, an equally large
gene was found to harbor no non-synonymous variants
(among the 44 of 45 coding exons that were successfully
sequenced, 7.3 kb). We also identified three known poly-
glutamine repeat polymorphisms, one in exon 20 of
NCOA3.[27], one in exon 15 of NCOR2.[28], and one in
exon 4 of SMARCA2[29]; associations with these repeat
polymorphisms and breast cancer risk will be examined in
future studies. All non-synonymous, in-frame in/del and
splice-site variants were targeted for association testing (as
discussed in the methods) in the breast cancer case-con-
trol study in the MEC (1,612 cases and 1,961 controls). A
detailed list of the coding variants examined in the breast
cancer study, and their frequencies in each racial/ethnic
population is provided (see Additional file 1, Supplemen-
tary table 1). Only one variant was found in a single pop-
ulation (NCOA3, Met391Val; African Americans, MAF
1.6%) and all variants were in Hardy-Weinberg Equilib-
rium among controls (p > 0.05) in at least four of the five
ethnic groups.
Allelic associations with breast cancer risk
The median age of the breast cancer cases and controls
was 65 and 63 years, respectively. The associations with
established breast cancer risk factors for each ethnic group
were generally as expected. Briefly, among postmenopau-
sal women, compared to controls, cases were more likely
to be heavier and to have used hormone therapy. Cases
also reported having an earlier age of menarche and were
more likely to report a family history of breast cancer,
than controls (Additional file 1, Supplementary Table 2).
The associations of each coding variant with breast cancer
risk are presented in Table 2. We observed nominally sig-
nificant positive associations (p ≤ 0.05) with two variants
in ethnic-pooled analyses (NCOR2: His52Arg, OR = 1.79;
95% CI, 1.05–3.05; CALCOCO1: Arg12His, OR = 2.29;
95% CI, 1.00–5.26). His52Arg in NCOR2 was also found
to be significantly positively associated regional/meta-
static breast cancer (OR = 2.25; 95% CI, 1.15–4.38) while
Arg12His in CALCOCO1 was more closely associated with
ER-positive breast cancer (OR = 2.83; 95% CI, 1.19–6.74)
and regional/metastatic disease (OR = 3.19; 95% CI,
1.12–9.11). Associations were not statistically signifi-
cantly different between disease subgroups (stage or ER
status) however for either variant. Both of these variants
were relatively rare among controls in each population,
with MAFs of ≤ 2.6% (1 homozygous carrier) and ≤ 0.5%
(0 homozygous carriers) for His52Arg and Arg12His,
respectively. The associations with each coding variant by
race-ethnicity and the genotype counts for each variant are
provided (see Additional file 1, Supplementary tables 1
and 3).
Allelic associations were also examined by ER status and
stage of disease. We observed significant positive associa-
tions with single variants in EP300 (Ser507Gly), NCOR2
(Lys980Thr) and CREBBP (Val992Ile) among ER-negative
tumors (Table 2), and significant heterogeneity by ER sta-
tus in case-only analyses (p < 0.01) for Ser507Gly and
Val992Ile. There was a statistically significant positive
association with CCND1  (Pro241Pro) and an inverse
association with EP300 (Ile997Val) for ER-positive cases
(Table 2). In addition to the previously noted associations
with His52Arg in NCOR2 and Arg12His in CALCOCO1,
we observed a significant positive association with
Ala407Ser in NCOA2 and advanced disease and nomi-
nally significant heterogeneity (p < 0.05) by disease stage
for variants Ala83Thr and Ser448Asn in FOXA1 and vari-
ants Ser2311Gly and Ala2496Thr in NCOR2.
We also evaluated allelic effect modification by known
breast cancer risk factors that are associated with steroid
hormone exposure, with the a priori hypothesis being that
conditions related to long-term steroid hormone expo-
sure (i.e. greater postmenopausal weight, early age at
menarche and ever use of hormone therapy) may influ-
ence the penetrance associated with these candidate cod-
ing variants (see Additional file 1, Supplementary tables
4–6). We observed very little evidence to support this
hypothesis and only two nominally statistically signifi-
cant interactions (Ala2007Thr in NCOR2  and age at
menarche (LRT, p = 0.04); and Ala83Thr in FOXA1 and
BMI (LRT, p = 0.00054)). Of note we observed a border-
line significant positive association with the common
Pro241Pro variant in CCND1 among current users of HRT
(OR = 1.21; 95% CI, 1.00–1.46), however no significant
interactions were observed by postmenopausal hormone
use status (see Additional file 1, Supplementary table 6).
Discussion
Inherited susceptibility to breast cancer is associated with
a wide spectrum of allelic variants that convey varying
degrees of risk (reviewed in [30]). Rare mutations in the
coding sequence of BRCA1 and BRCA2 and a growing
number of other genes involved in maintaining genomic
stability have been shown to confer high to moderate risks
of breast cancer. More recently, genome-wide scans ofBMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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Table 2: The Association of Coding Variants in Candidate Coactivator and Corepressor-related Genes with Breast Cancer Risk.
Gene/Variant MAF, rangea All Groups 1,612 cases/
1,961 controls
ER+ 1090 cases ER- 293 cases Localized 1187 cases Regional/Metastatic 420 
cases
OR(95% CI)b OR(95% CI)b OR(95% CI)b OR(95% CI)b OR(95% CI)b
EP300
Ser507Gly 0–0.020 1.01(0.55–1.85) 0.73(0.35–1.54)c 2.61(1.15–5.92)c 1.01(0.53–1.95) 1.05(0.39–2.83)
Ile997Val 0.023–0.483 0.92(0.81–1.04) 0.86(0.74–0.99) 1.08(0.86–1.36) 0.94(0.82–1.08) 0.87(0.71–1.06)
Pro1986Leu 0–0.007 0.88(0.21–3.73) 1.12(0.26–4.78) -d 0.67(0.13–3.57) 1.35(0.16–11.56)
Gln2223Pro 0–0.036 1.03(0.70–1.52) 1.02(0.66–1.57) 0.91(0.43–1.93) 0.95(0.62–1.47) 1.31(0.75–2.27)
CCND1
Pro241Pro 0.244–0.539 1.07(0.97–1.18) 1.12(1.00–1.26) 1.04(0.86–1.26) 1.08(0.96–1.20) 1.06(0.90–1.24)
NCOA1
Pro1272Ser 0–0.022 1.11(0.69–1.78) 1.04(0.60–1.79) 1.09(0.46–2.59) 1.31(0.80–2.14) 0.62(0.24–1.58)
NCOA2
Ala407Ser 0–0.005 2.25(0.73–6.96) 2.09(0.55–7.89) 2.85(0.67–12.13) 1.23(0.29–5.24) 4.21(1.19–14.85)
Asn1212Ser 0–0.012 1.08(0.45–2.56) 1.27(0.49–3.34) 1.37(0.37–5.00) 0.91(0.33–2.50) 1.56(0.49–4.99)
Met1282Ile 0.019–0.142 1.06(0.87–1.29) 1.07(0.86–1.33) 0.99(0.67–1.46) 1.10(0.89–1.36) 0.94(0.67–1.31)
NCOA3
Arg218Cys 0–0.079 0.88(0.68–1.13) 0.90(0.68–1.21) 0.84(0.53–1.33) 0.77(0.58–1.03) 1.13(0.79–1.62)
Met391Val 0–0.016 0.93(0.41–2.13) 1.25(0.49–3.18) 0.33(0.04–2.54) 0.93(0.37–2.35) 0.87(0.24–3.09)
Pro559Ser 0–0.037 1.13(0.68–1.89) 1.48(0.84–2.61) 0.77(0.29–2.03) 1.35(0.78–2.32) 0.65(0.25–1.72)
Gln586His 0.020–0.086 1.00(0.80–1.23) 0.97(0.77–1.24) 1.16(0.80–1.69) 1.07(0.85–1.34) 0.84(0.58–1.20)
Ser662Phe 0–< 0.001 -d -d -d -d -d
FOXA1
Ala83Thr 0.118–0.580 0.99(0.89–1.10) 0.99(0.88–1.12) 1.07(0.88–1.30) 0.94(0.83–1.06)c 1.14(0.96–1.35)c
Ser448Asn 0.002–0.057 1.09(0.84–1.42) 1.29(0.97–1.71) 0.69(0.39–1.22) 0.99(0.74–1.33)c 1.39(0.96–2.02)c
MPG
Val242Leu 0–0.002 1.62(0.36–7.29) 2.70(0.59–12.26) -d 0.61(0.06–5.95) 4.32(0.86–21.62)
NCOR1
Val1996/1997del 0–0.028 0.96(0.52–1.77) 0.93(0.44–1.96) 1.22(0.50–2.98) 0.85(0.41–1.74) 1.24(0.53–2.87)
NCOR2
Thr35Met 0–0.025 0.18(0.02–1.37) 0.22(0.03–1.72) -d -d 0.71(0.09–5.59)
His52Arg 0–0.026 1.79(1.05–3.05) 1.52(0.81–2.86) 2.09(0.97–4.50) 1.57(0.84–2.96) 2.25(1.15–4.38)
Gly783Glu 0.001–0.125 1.16(0.97–1.39) 1.19(0.98–1.46) 1.03(0.74–1.44) 1.21(0.99–1.46) 1.05(0.79–1.40)
Lys980Thr 0–0.014 1.33(0.67–2.67) 1.16(0.54–2.52) 3.34(1.17–9.53) 1.43(0.69–2.98) 1.16(0.33–4.09)
Ala995Gly 0–0.078 0.95(0.67–1.36) 0.98(0.64–1.50) 1.13(0.66–1.93) 0.99(0.67–1.47) 0.83(0.47–1.46)
Ser1525Thr 0–0.028 0.91(0.51–1.62) 0.75(0.35–1.59) 1.48(0.69–3.20) 0.82(0.42–1.59) 1.16(0.50–2.66)
Ala1706Thr 0.060–0.209 0.99(0.86–1.13) 0.99(0.85–1.15) 0.99(0.77–1.26) 0.96(0.83–1.12) 1.02(0.83–1.26)
Ala2007Thr 0.012–0.049 1.00(0.78–1.29) 0.93(0.69–1.25) 0.97(0.60–1.55) 1.03(0.78–1.36) 0.95(0.63–1.44)
Ala2011Val 0–0.011 1.15(0.48–2.74) 1.65(0.67–4.06) 0.58(0.07–4.60) 0.89(0.30–2.65) 1.83(0.61–5.49)
Thr2216Pro 0–0.022 1.04(0.56–1.93) 1.14(0.57–2.30) 1.02(0.34–3.03) 1.14(0.58–2.22) 0.84(0.28–2.48)
Ser2311Gly 0.001–0.060 0.93(0.64–1.34) 0.90(0.60–1.36) 0.73(0.32–1.67) 1.08(0.73–1.58)c 0.48(0.21–1.09)c
Ala2496Thr 0–0.062 0.96(0.68–1.38) 1.01(0.69–1.49) 0.57(0.23–1.41) 1.12(0.77–1.63)c 0.46(0.20–1.05)c
CALCOCO1
Arg12His 0–0.005 2.29(1.00–5.26) 2.83(1.19–6.74) 0.76(0.09–6.09) 1.89(0.75–4.75) 3.19(1.12–9.11)
Arg393Lys 0.140–0.365 0.93(0.82–1.05) 0.92(0.80–1.05) 1.01(0.80–1.26) 0.90(0.79–1.03) 0.98(0.80–1.19)
Ala527Thr 0–0.014 0.92(0.41–2.11) 0.82(0.29–2.31) 0.34(0.04–2.62) 1.21(0.51–2.84) 0.29(0.04–2.24)
Gly561Val 0–0.011 1.17(0.57–2.39) 1.34(0.61–2.93) 0.81(0.18–3.60) 1.23(0.56–2.68) 1.10(0.36–3.32)
Thr639Pro 0–0.067 0.95(0.64–1.42) 1.00(0.63–1.60) 0.64(0.30–1.37) 0.84(0.53–1.33) 1.26(0.72–2.20)
CREBBP
Pro858Ser 0–0.006 0.67(0.16–2.81) 0.76(0.15–3.98) 1.12(0.13–9.77) 0.63(0.12–3.26) 0.87(0.10–7.57)
Thr910Ala 0–0.002 1.11(0.27–4.48) 1.58(0.39–6.49) -d 1.17(0.26–5.34) 1.11(0.12–10.01)
Val992Ile 0–0.036 1.14(0.68–1.92) 0.60(0.28–1.28)c 2.20(1.10–4.39)c 1.19(0.67–2.12) 1.10(0.49–2.45)
Gly2229Ser 0–0.011 1.69(0.70–4.07) 1.66(0.61–4.53) 1.09(0.23–5.15) 1.58(0.60–4.17) 1.92(0.58–6.35)
SMARCA2
Asp1546Glu 0.129–0.242 1.07(0.94–1.21) 1.12(0.98–1.29) 0.92(0.73–1.16) 1.07(0.93–1.22) 1.07(0.88–1.30)
a Minor allele frequency among controls across populations.
b Adjusted for age and race. OR for gene dosage effects.
c Case-only analysis: ER+ vs ER-, p < 0.01; Localized vs Regional/Metastatic, p < 0.05
d OR can not be calculated because of small numbers of cases or controls.BMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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breast cancer in populations of European ancestry have
identified a limited number of common alleles associated
with more modest risks of breast cancer (OR ~1.1–1.2 per
allele). [31-34] Genome-wide scanning approaches have
been shown to be powerful for discovering common var-
iants that influence complex disease phenotypes; how-
ever, these approaches currently fail to comprehensively
survey coding variation, particularly uncommon alleles in
non-European populations. At present, the only way to
fully enumerate and comprehensively assess the coding-
variant model for breast cancer susceptibility is by direct
resequencing of candidate loci. This candidate gene rese-
quencing strategy has been successful in identifying rare
truncating mutations in a number of genes that confer
approximately 2-fold risks of breast cancer (e.g. PALB2
and BRIP1).[35,36] This approach has also been success-
ful for identifying rare alleles that act collectively to influ-
ence other complex traits and cancer phenotypes, with
examples including variants in candidate genes that influ-
ence plasma lipid levels [37] and risk of developing color-
ectal adenomas.[38]
In this study, we examined the role of coding variation in
breast cancer in multiple populations, focusing on a set of
17 candidate steroid hormone coactivator and corepres-
sor-related genes selected based on their ability to interact
with the estrogen receptor transcription complex and
potentially modulate response to estrogen in breast tissue.
Sequencing of the coding exons in a multi-ethnic panel of
95 women with advanced breast cancer provided 85%
power to identify putative functional coding variants with
frequencies as low as 1% in the combined sample. The
breast cancer case-control study utilized for association
testing was also well-powered to detect nominally signifi-
cant effects as low as 1.8 for rare alleles (1% MAF, 81%
power) and 1.35 for more common alleles (5% MAF, 83%
power). This study was also well-powered to detect effects
as low as 1.36 for more common alleles (10% MAF, 82%
power) after correcting for the number of tests performed
(n = 40, α = 0.00125). The multiethnic nature of this
study was designed to allow for investigating a wide range
of risk alleles; however, we found the vast majority of cod-
ing variants to be present in more than one population
(39 of 40 variants). In this study, we observed nominally
significant associations with only 2 variants and breast
cancer risk (His52Arg in NCOR2  and Arg12His in
CALCOCO1), which is in line with expectation based on
the number of tests that were performed (2 of 40 = 5%).
The observation that these variants were also significantly
associated with stage and ER status will need to be con-
firmed in other studies.
Aside from CCND1, coding variation in only a small
number of these genes has been investigated in relation to
breast cancer risk [39,40]. The Pro241Pro splice-site vari-
ant in CCND1 has been examined extensively, with some
studies reporting a positive association, [41-43] and oth-
ers finding no significant association [44-46]. We
observed no significant association with this variant, and
much larger collaborative efforts, such as the Breast Can-
cer Association Consortium [47], will be needed to rule
out weak effects (RR < 1.15) for this functional variant.
Our data support those of Wirtenberger et al.[40] who
reported no association with the Ile997Val or
Gln2223Pro variants in EP300. However, we did observe
nominally significant associations between Pro241Pro in
CCND1 and Ile997Val in EP300 and risk of ER-positive
breast cancer. These findings are noteworthy as both of
these variants are relatively common in the population
and will need to be confirmed in other large studies. An
inverse association has also been reported with the
Gln586His variant in NCOA3 (p = 0.03) in a European
study (775 cases and 1,628 controls), which we were una-
ble to replicate in our much larger study [39]. The
glutamine repeat polymorphism in NCOA3 has also been
investigated in multiple populations, with the vast major-
ity of studies reporting no significant correlation between
repeat genotype and breast cancer incidence. [48-52]
Although we conducted a comprehensive assessment of
coding variants in these candidate genes, there are a
number of limitations to our study that should be consid-
ered when interpreting our findings. First, our resequenc-
ing strategy most likely missed rare coding variants in
these genes, including those which may be population- or
subject-specific. Second, we did not enrich our sequencing
panel with cases with a family history of breast cancer who
may be more genetically susceptible and for whom a cod-
ing-variant genetic model may be more probable. Nor did
we enrich our panel with cases with ER-positive tumors
which may increase the likelihood for detecting putative
functional coding variants in these genes based on their
known modes of action. Most of the variants that we iden-
tified were rare, so power was limited. Future studies of
these loci and other steroid hormone receptor coactivator
and corepressor genes will require even larger samples
from these defined population subgroups to ensure com-
plete ascertainment of all rare coding alleles, followed by
robust association studies with greater power to assess
more modest effects.
Conclusion
This study suggests that common coding variation in
these 17 candidate steroid hormone receptor coactivator
and corepressor genes does not make a substantial contri-
bution to breast cancer risk in the general population. Cat-
aloging and testing of coding variants in coactivator and
corepressor genes should continue and may serve as a val-
uable resource for investigations of other hormone-
related phenotypes, such as mammographic density, andBMC Cancer 2009, 9:43 http://www.biomedcentral.com/1471-2407/9/43
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of inter-individual response to hormonal therapies used
for cancer treatment and prevention.
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